MME and hydrops fetalis: Sacubitril/valsartan (S/V; formerly termed as LCZ696), afirst-in-class angiotensin receptor/neprilysin inhibitor, brought a significantshift in the management of HF with reduced ejection fraction by modulating bothrenin-angiotensin-aldosterone system (angiotensin II type I receptor blockage byvalsartan) and natriuretic peptide system (neprilysin inhibition by sacubitril)pathways.